AccessClosure launches Mynx Cadence Vascular Closure Device

AccessClosure, Inc., the U.S. market leader in extravascular closure devices, announced today the launch of its next generation product, the Mynx Cadence Vascular Closure Device (VCD).  With its simpler design and improved ease-of-use, Mynx Cadence offers physicians smoother device deployment while maintaining all the benefits of the original Mynx.

"We are extremely excited about the launch of the Mynx Cadence," said Gregory D. Casciaro, President and CEO of AccessClosure.   "Designing enhanced solutions for vascular closure is our top priority and the design changes incorporated into the Mynx Cadence make it easier to use while maintaining the same feel our users have grown accustomed to.  We believe this device provides an excellent platform for growth as we continue to expand our user base."

Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy.  A definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling.  Additionally, a single marker on the advancer tube removes any guesswork around sealant compression.  Finally, a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation.  These changes result in more consistent sealant delivery every time.  

"My initial experience with the Mynx Cadence has been very positive," said Elias Kassab, MD, FACC, an Interventional Cardiologist from Oakwood Hospital in Detroit, Michigan.  "The design changes inspire increased confidence in the device, but I don't feel that I've lost any of the tactile feedback I'm used to with the Mynx.  These changes truly improve the experience of deploying the Mynx."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but a healed artery. The Mynx received its first FDA approval in May 2007, has been used in over 700,000 procedures, and is available in two sizes for 5F and 6F/7F procedural sheaths.  

Source:

AccessClosure, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Spermidine regulates RIPK1 to combat diabetes and vascular damage